All Product News

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Aripiprazole Orally Disintegrating Tablets USP, 10 mg and 15 mg. Aurobindo Pharma’s Aripiprazole Orally Disintegrating Tablets USP, are an AB-rated generic equivalent to the reference listed drug (RLD), Abilify Discmelt® Orally Disintegrating […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Betamethasone Dipropionate Cream USP, 0.05%. Aurobindo Pharma’s Betamethasone Dipropionate Cream USP, are an AB-rated generic equivalent to the reference listed drug (RLD), Betamethasone Dipropionate Cream USP, manufactured by Fougera Pharmaceuticals Inc. Betamethasone […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Bisoprolol Fumarate and Hydrochlorothiazide Tablets USP, 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg. Aurobindo Pharma’s Bisoprolol Fumarate and Hydrochlorothiazide Tablets USP, are an AB-rated generic equivalent to the reference […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Cariprazine Capsules, 1.5 mg, 3 mg, and 6 mg. Aurobindo Pharma’s Cariprazine Capsules are an AB-rated generic equivalent to the reference listed drug (RLD), Vraylar Capsules manufactured by AbbVie Inc. Cariprazine Capsules […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Potassium Chloride Oral Solution USP, 10% (20 mEq/15 mL) and 20% (40 mEq/15 mL). Aurobindo Pharma’s Potassium Chloride Oral Solution USP, are an AB-rated generic equivalent to the reference listed drug (RLD), […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Fosfomycin Tromethamine Granules for Oral Solution, 3 grams (Single-Dose Sachet). Aurobindo Pharma’s Fosfomycin Tromethamine Granules for Oral Solution, are an AB-rated generic equivalent to the reference listed drug (RLD), Monurol® Granules for […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Linagliptin Tablets, 5 mg. Aurobindo Pharma’s Linagliptin Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Tradjenta Tablets manufactured by Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer). Linagliptin Tablets are indicated […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Naproxen Oral Suspension USP, 125 mg/5 mL. Aurobindo Pharma’s Naproxen Oral Suspension, are an AB-rated generic equivalent to the reference listed drug (RLD), Naprosyn Oral Suspension manufactured by Atnahs Pharma US Limited. […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg. Aurobindo Pharma’s Prochlorperazine Maleate Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Compazine Tablets manufactured by GlaxoSmithKline (GSK) Prochlorperazine […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Deferasirox Oral Granules, 90 mg,180 mg, and 360 mg. Aurobindo Pharma’s Deferasirox Oral Granules, are an AB-rated generic equivalent to the reference listed drug (RLD), Jadenu Sprinkle Granules manufactured by Novartis Pharmaceuticals […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Pirfenidone Tablets USP, 267 mg and 801 mg. Aurobindo Pharma’s Pirfenidone Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Esbriet Tablets manufactured by Genentech Inc. (a subsidiary of […]

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Lidocaine Hydrochloride Oral Topical Solution USP, 2%. Aurobindo Pharma’s Lidocaine Hydrochloride Oral Topical Solution, are an AB-rated generic equivalent to the reference listed drug (RLD), Xylocaine Oral Topical Solution manufactured by Fresenius […]